Anti‐envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection. Issue 11 (13th July 2016)

• Record Type: Journal Article
• Authors: Swann, R. E.; Mandalou, P.; Robinson, M. W.; Ow, M. M.; Foung, S. K. H.; McLauchlan, J.; Patel, A. H.; Cramp, M. E.
• Is Part Of: Journal of viral hepatitis. Volume 23:Issue 11(2016)
• Page Start: 873
• Page End: 880
• Publication Date: 2016-07-13
• Subjects: E1E2 -- exposed uninfected (EU) -- injection drug user (IDU) -- neutralization -- neutralizing antibodies; Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.12568
• Languages: English
• ISSNs: 1352-0504

Abstract

Summary: Injection drug users uninfected by hepatitis C virus (HCV) despite likely repeated exposure through high‐risk behaviour are well documented. Factors preventing infection in these individuals are incompletely understood. Here, we looked for anti‐HCV‐envelope antibody responses in a cohort of repeatedly exposed but uninfected subjects. Forty‐two hepatitis C diagnostic antibody‐ and RNA‐negative injection drug users at high risk of exposure were studied and findings compared to healthy controls and cases with chronic HCV infection. Purified IgGs from sera were tested by ELISA for binding to genotype 1a and 3a envelope glycoproteins E1E2 with further testing for IgG and IgM reactivity against soluble E2. Virus‐neutralizing activity was assessed using an HCV pseudoparticle system. Uninfected subjects demonstrated significantly greater IgG and IgM reactivities to envelope glycoproteins than healthy controls with IgG from 6 individuals additionally showing significant neutralization. This study is the first to describe humoral immunological responses targeting the HCV envelope, important for viral neutralization, in exposed uninfected individuals. A subset of these cases also had evidence of viral neutralization via anti‐envelope antibodies. In addition to confirming viral exposure, the presence of specific anti‐envelope antibodies may be a factor that helps these individuals resist HCV infection.